Tamoxifen for early breast cancer: an overview of the randomised trials
- 1 May 1998
- journal article
- Published by Elsevier in The Lancet
- Vol. 351 (9114), 1451-1467
- https://doi.org/10.1016/s0140-6736(97)11423-4
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Five Years of Tamoxifen--or More?JNCI Journal of the National Cancer Institute, 1996
- Preliminary Results From the Cancer Research Campaign Trial Evaluating Tamoxifen Duration in Women Aged Fifty Years or Older With Breast CancerJNCI Journal of the National Cancer Institute, 1996
- Postchemotherapy Adjuvant Tamoxifen Therapy Beyond Five Years in Patients With Lymph Node-Positive Breast CancerJNCI Journal of the National Cancer Institute, 1996
- Randomized Trial of Two Versus Five Years of Adjuvant Tamoxifen for Postmenopausal Early Stage Breast CancerJNCI Journal of the National Cancer Institute, 1996
- Five Versus More Than Five Years of Tamoxifen Therapy for Breast Cancer Patients With Negative Lymph Nodes and Estrogen Receptor-Positive TumorsJNCI Journal of the National Cancer Institute, 1996
- Effects of Radiotherapy and Surgery in Early Breast Cancer — An Overview of the Randomized TrialsNew England Journal of Medicine, 1995
- Adjuvant Tamoxifen Therapy for Early Stage Breast Cancer and Second Primary MalignanciesJNCI Journal of the National Cancer Institute, 1995
- Endometrial Cancer in Tamoxifen-Treated Breast Cancer Patients: Findings From the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 *JNCI Journal of the National Cancer Institute, 1994
- Radiotherapy, chemotherapy, and tamoxifen as adjuncts to surgery in early breast cancer: A summary of three randomized trialsInternational Journal of Radiation Oncology*Biology*Physics, 1989
- Effects of Adjuvant Tamoxifen and of Cytotoxic Therapy on Mortality in Early Breast CancerNew England Journal of Medicine, 1988